Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization roadmap. But their roadmap with Voyager is clearer, although Early Access revenue remains too limited to prove it can turn into recurring sales. Unfortunately, the main risks going forward are still tied to potential execution setbacks, its ongoing cash burn, and a likely capital raise by 2027. NAUT’s market cap now roughly matches its liquid resources. So, I think the margin of safety is good enough to be bullish on management’s goals for 2026 and 2027.

Nautilus Biotechnology, Inc. ( NAUT ) is a development-stage life sciences company that's developing the Voyager platform. They recently reported Q2 results , and I believe their core thesis remains the same, at least as far as their